Phase 3 N=152 Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
Preterm Delivery
Primary: Gestational Age at Delivery — 29.2; 29.5 weeks.
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=77 Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)
Primary: DB Phase: Change From Baseline In Serum Alkaline Phosphatase (ALP) — -105.05; -110.19; -26.76 U/L — p=0.0434
N/A N=102 Evaluation of Pain With Radiesse® With Lidocaine for Nasolabial Folds
Nasolabial Folds
Primary: Pain Score Using a 10-cm Visual Analog Scale (VAS) for Pain (0 = no Pain, 10 = Very Severe Pain) — 2.32; 6.73 units on a scale — p=<0.0001
Phase 4 N=9 Growth Hormone and Endothelial Function in Children
Growth Hormone Deficiency · Panhypopituitarism · Short Stature
Primary: Reactive Hyperemic Response After 3 Months of Growth Hormone — 21.077 ml/dl min — p=0.644
N/A N=64 Effect of Omega-3 Supplementation During Pregnancy on Regulation of Stress
Healthy Pregnant Women
Primary: Maternal Cortisol Levels — 0.28; 0.34 ug/dL
Phase 2 N=36 Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Leukemia
Primary: Percentage of Participants With Complete Remission (CR) — 44 percentage of participants
N/A N=49 Use of NAC in Alleviation of Hangover Symptoms
Hangover Symptoms, NAC
Primary: Hangover Symptom Scale — 10; 13; 1; 1 units on a scale — p=0.45
N/A N=90 A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites — 88.01 percentage…
Phase 2 N=65 Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response — 0.42; 0.52 proportion of participants
Phase 1 N=42 Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application
Healthy Volunteers
Primary: Baseline Corrected FSH Area Under the Serum Concentration-time Curve From Zero to the Last Quantifiable Measurement [AUC(0-last)] — 18.96; 10.47 nanograms*hours/mL…
N/A N=48 A Long Term Follow up of Anterior Meshes for Recurrent Prolapse
Genital Diseases, Female · Pelvic Organ Prolapse
Primary: The Number of Participants With a Current Mesh Erosion or Treated for a Mesh Erosion Since Inserted — 5 Participants
Phase 1 N=30 Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Parkinson's Disease
Primary: Efficacy of DHA - Change in Blood ng/dL Levels — 102.18; -13.20 ng/dL - Blood
N/A N=51 A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects
Healthy Controls
Primary: fMRI Signal Changes — 0.82; 0.43; -0.02; 0.55 Beta value
N/A N=30 Effect of Endoplasmic Reticulum Stress on Metabolic Function
Insulin Resistance · Diabetes · Obesity
Primary: Body Composition — 39; 39; 37; 39 percentage
Phase 3 N=343 AM-101 in the Treatment of Acute Tinnitus 2
Tinnitus
Primary: Efficacy: Change in Patient-reported Tinnitus Loudness Questionnaire (TLQ) Improvement From Baseline to Follow up Visit 3 (FUV3) — 0.80; 0.63 units on a scale — p=0.32